Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)
ctDNA detectability and its dynamic changes during treatment may have potential clinical utility in patients with metastatic melanoma, offering a valuable non-invasive tool for monitoring disease and treatment response. The small sample size limited the statistical power of the analysis. Further studies with larger cohorts are needed to validate its role in routine clinical practice.
Authors
- Roberta Minari (ORCID: https://orcid.org/0000-0002-4808-0308)
- Michele Montrone (ORCID: https://orcid.org/0000-0002-8568-7723)
- M.J.C. Gregorio (ORCID: https://orcid.org/0000-0002-9867-6740)
- M. Della Giulia (ORCID: https://orcid.org/0000-0002-4818-5142)
- Roberta Manuguerra (ORCID: https://orcid.org/0000-0002-5446-8229)
- Palazzi Carolina
- Azzoni Cinzia
- Bottarelli Lorena
- P. Della Monica
- Tiseo Marcello
- Martines Gianmarco
- Perrone Fabiana
- Verzè Michela
- Giudice Giulia Claire
Institutions
- University of Parma (IT)
- Portsmouth Hospitals NHS Trust (GB)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- The Journal of Liquid Biopsy
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1016/j.jlb.2025.100295
- Citations
- 2
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.87